Dragonfly Therapeutics, Inc.’s Post

Longitude portfolio company Quanta Therapeutics recently announced two exciting clinical trial updates from its pipeline of KRAS-directed drug candidates: - The first patient has been dosed in the monotherapy portion of a Phase 1 clinical trial evaluating QTX3046, a KRASG12D-selective inhibitor. - Patient dosing has begun in the combination portion of the ongoing Phase 1 clinical trial assessing QTX3034, G12D-preferring multi-KRAS inhibitor, and cetuximab. The company focuses on developing innovative, oral therapeutics for RAS-driven cancers, and both clinical trials are enrolling patients with KRASG12D-mutated advanced solid tumors. Learn more about the clinical trials here: https://lnkd.in/eRHZAqCZ #biotech #clinicaltrials #cancerresearch

Sponsors are seeing 192 days of delay on each phase 2 oncology trial and incurring $1.85m in avoidable direct costs due to imaging inaccuracies alone. Click the article and try the free cost calculator to learn more about how Yunu saves sponsors time and money. References are provided in the article validating this stunning reality. https://lnkd.in/gcHPJAw6

In #ClinicalTrials investigating Antibody Drug Conjugates (#ADC), worldwide regulators are asking sponsors to monitor for ILD toxicity. Understand the implications and how to meet #regulatory expectations in this quick read by Calyx's Rohit Sood MD., PhD., CFP. https://lnkd.in/e6tJ2bfg #MedicalImaging #Oncology #ChooseCalyx

In #ClinicalTrials investigating Antibody Drug Conjugates (#ADC), worldwide regulators are asking sponsors to monitor for ILD toxicity. Understand the implications and how to meet #regulatory expectations in this quick read by Calyx's Rohit Sood MD., PhD., CFP https://lnkd.in/e6tJ2bfg #MedicalImaging #Oncology #ChooseCalyx

In #ClinicalTrials investigating Antibody Drug Conjugates (#ADC), worldwide regulators are asking sponsors to monitor for ILD toxicity. Understand the implications and how to meet #regulatory expectations in this quick read by Calyx's Rohit Sood MD., PhD., CFP. https://lnkd.in/e6tJ2bfg #MedicalImaging #Oncology #ChooseCalyx

In #ClinicalTrials investigating Antibody Drug Conjugates (#ADC), worldwide regulators are asking sponsors to monitor for ILD toxicity. Understand the implications and how to meet #regulatory expectations in this quick read by Calyx's Rohit Sood MD., PhD., CFP. https://lnkd.in/e6tJ2bfg #MedicalImaging #Oncology #ChooseCalyx

The Ultimate Guide to Mouse Clinical Trials is the essential free resource to accelerate your oncology research and make more informed decisions in your drug development process. Download our latest white paper and discover how to maximize the potential of your preclinical studies with actionable insights, including: ✅Enhanced Clinical Translation: Learn how PDX models can improve the predictability of preclinical studies, aligning them more closely with clinical outcomes. ✅Optimized Drug Discovery: Find out how leveraging PDX models helps reduce attrition rates in oncology drug development by providing more accurate efficacy assessments. ✅Innovative Study Designs: Get expert guidance on designing and executing Mouse Clinical Trials (MCTs) that reflect human population diversity, yielding more relevant results. ✅Biomarker Discovery: Discover how MCTs enable the identification of biomarkers that can significantly boost the success of your clinical trials, especially in critical phases. Download the White Paper now! https://hubs.la/Q02Q12ND0

Accelerate your oncology research with “The Ultimate Guide to Mouse Clinical Trials,” a free resource offering actionable insights on PDX models, drug discovery, study designs, and biomarker discovery. Download the white paper now! https://hubs.la/Q02Q12ND0 #OncologyResearch #MouseClinicalTrials #PDXModels #DrugDiscovery #BiomarkerDiscovery #PreclinicalStudies #ClinicalTranslation #InnovativeResearch

Interesting study that supports it can be done! Diversity without delay! No doubt in takes proactive planning and methodologies that are emerging as good practices. #communityengagement #diversityequityinclusion #drugdevelopment

Medical researchers have dreamt of finding a “magic bullet” that will just target cancerous cells since at least 1900. Antibody-drug conjugates (ADCs) look like the best shot within oncology dealmaking. More than ten ADCs have been approved and become commercially available this century, with around 100 in clinical trials to date. As a result of the segment’s potential, Big Pharma and investors have been pumping money into ADCs, both in North America and Europe. European ADC for oncology deals began to boom in 2022, with six transactions worth EUR 1.2bn, according to Mergermarket data. This showed massive growth from one deal worth EUR 87m in 2021. Volumes fell again in 2023 and 2024. More here: https://lnkd.in/eNANzr7G